Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Longterm HPN With Two Lipid Emulsions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age: 18-80 years~* Male and female patients~* Patients with a newly indicated need of long-term home parenteral nutrition (HPN) for at least 8 weeks~* Patients with an insufficient resorption capacity of the colon that may not be compensated by enteral nutrition~* mentally and physically able to adhere to study procedures.~* Females agree to apply adequate contraception~Exclusion Criteria:~* Participation in a clinical study with an investigational drug within one month prior to the start of study~* Patients with sepsis, severe sepsis and septic shock~* Known or suspected drug abuse~* General contra indications for infusion therapy such as acute pulmonary edema, hyperhydration and decompensated cardiac insufficiency~* Pregnancy and lactation~* Autoimmune disease as e.g. HIV~* Known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients~* Hemodynamic failure of any origin (hemorrhagic shock, myocardial infarction, cardiac failure)~* Alterations of coagulation (thrombocytes \<150.000 mm3), PT \< 50%, PTT \> 40 sec~* Diabetes mellitus with known ketoacidosis within 7 days before onset of study~* Renal insufficiency with serum creatinine \> 1.4 mg/dL(\>124 mmol/L)~* Patients with severe liver dysfunction with bilirubin \>2.5 mg/dL (\> 43 µmol/L)~* Lipid disorders, in particular fasting serum triglycerides \> 250 mg/dL (\>2.86 mmol/L)~* necrotizing pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): treatment with Lipoplus \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)
- 2 (Type: ACTIVE_COMPARATOR): treatment with Lipofundin MCT \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)

Based on this trial design, predict the completion outcome and termination type (if applicable).